ALXO - Alx Oncology Holdings 
Alx Oncology Holdings  Logo

ALXO - Alx Oncology Holdings 

https://www.alxoncology.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.

52W High
$2.36
52W Low
$0.40
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.12
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-2.35
EV/Revenue (<3 favorable)
4254.36
P/S (TTM) (<3 favorable)
5906.24
P/B (<3 favorable)
1.01
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
2.58%
Institutions (25–75% balanced)
68.66%
Shares Outstanding
53,551,000
Float
31,604,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
107,000
EPS (TTM)
-2.16
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-1.04%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
0.1227
Previous
0.1388
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025